This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citic Securities Sticks to Their Buy Rating for CSPC Pharmaceutical Group (CHJTF)

Tipranks - Tipranks - Fri Jun 5, 9:00PM CDT

In a report released on June 3, from Citic Securities maintained a Buy rating on CSPC Pharmaceutical Group, with a price target of HK$18.00. The company’s shares closed last Friday at HK$7.25.

Claim 55% Off TipRanks

CSPC Pharmaceutical Group has an analyst consensus of Moderate Buy, with a price target consensus of HK$11.68, which is a 61.05% upside from current levels. In a report released on May 28, CMB International Securities also maintained a Buy rating on the stock with a HK$13.05 price target.

See today’s best-performing stocks on TipRanks >>

Based on CSPC Pharmaceutical Group’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$12.52 billion and a net profit of HK$1.31 billion. In comparison, last year the company earned a revenue of HK$12.96 billion and had a net profit of HK$1.33 billion

Read More on CHJTF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).